Related Experiment Video

Updated: Oct 22, 2025

Method for Measuring the Activity of Deubiquitinating Enzymes in Cell Lines and Tissue Samples
09:45

Method for Measuring the Activity of Deubiquitinating Enzymes in Cell Lines and Tissue Samples

Published on: May 10, 2015

9.8K

Deubiquitinases in hematological malignancies

Hu Lei1, Jiaqi Wang2, Jiacheng Hu2

  • 1Department of Pathophysiology, International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. hulei@shsmu.edu.cn.

Biomarker Research
|August 29, 2021
PubMed

Insights

Deubiquitinases (DUBs) are key enzymes in cell regulation and emerging therapeutic targets for blood cancers. Inhibitors targeting DUBs show promise in treating leukemia, multiple myeloma, and lymphoma.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Deubiquitinases (DUBs) regulate protein stability and function by removing ubiquitin tags.
  • Specific DUBs like USP7, USP9X, and USP10 are implicated as therapeutic targets in hematological malignancies.
  • DUBs exhibit diverse roles, acting as oncogenes, tumor suppressors, or having context-dependent effects in cancer.

Purpose of the Study:

  • To review the biological roles of DUBs in various hematological malignancies.
  • To summarize the development and application of DUB inhibitors in cancer therapy.
  • To highlight DUBs as potential therapeutic targets for blood cancers.

Main Methods:

  • Literature review of DUBs in hematological malignancies.
  • Summary of DUB inhibitor development and preclinical/clinical data.
  • Analysis of DUBs' roles in leukemia, multiple myeloma, and lymphoma.

Main Results:

  • DUBs play critical roles in the pathogenesis of hematological malignancies.
  • Potent DUB inhibitors have been developed with promising efficacy in preclinical models.
  • Several DUB inhibitors have advanced to clinical trials for blood cancers.

Conclusions:

  • DUBs represent a promising class of therapeutic targets for hematological malignancies.
  • Targeting DUBs offers a novel strategy for treating leukemia, multiple myeloma, and lymphoma.
  • Further exploration of DUBs' functions will uncover new therapeutic avenues in hematologic oncology.
Keywords:
DeubiquitinasesHematological malignanciesLeukemiaLymphomaMultiple myeloma

More Related Videos

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones11:36

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones

Published on: July 25, 2019

11.0K
Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay07:05

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay

Published on: September 27, 2024

645

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.2K
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.9K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.5K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.3K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.0K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
2.0K